Drug interactions
Gemcitabine + Lisocabtagene maraleucel
Severity: Major
Gemcitabine and Lisocabtagene maraleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Gemcitabine is myelosuppressive, while lisocabtagene maraleucel is associated with prolonged cytopenias and immune deficiency. Combined exposure increases infection risk and may impair CAR-T cell collection or expansion.
What this interaction means in plain words
Gemcitabine and Lisocabtagene maraleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Gemcitabine belongs to Oncology; Lisocabtagene maraleucel belongs to Oncology.
Why it happens
Additive immunosuppression and myelosuppression; cytotoxic therapy may reduce CAR-T cell fitness and expansion.
What to do
Avoid chemotherapy except planned lymphodepletion around CAR-T infusion and observe the recommended washout before leukapheresis. Monitor blood counts and infections if chemotherapy is needed afterwards.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Gemcitabine and Lisocabtagene maraleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Gemcitabine
Other interactions of Lisocabtagene maraleucel
Frequently asked questions
Can I take Gemcitabine with Lisocabtagene maraleucel?
MediHelp rates the interaction as major. Gemcitabine and Lisocabtagene maraleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Gemcitabine is myelosuppressive, while lisocabtagene maraleucel is associated with prolonged cytopenias and immune deficiency. Combined exposure increases infection risk and may impair CAR-T cell collection or expansion.
How serious is the interaction between Gemcitabine and Lisocabtagene maraleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid chemotherapy except planned lymphodepletion around CAR-T infusion and observe the recommended washout before leukapheresis. Monitor blood counts and infections if chemotherapy is needed afterwards.
What other medicines interact with Gemcitabine?
MediHelp also lists interactions of Gemcitabine with, for example, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel, Belatacept. The full list is on the Gemcitabine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
